Loading…
Indian listed arm of P&G selling feminine hygiene (Whisper) and healthcare products (Vicks) in India.
Indian listed arm of P&G selling feminine hygiene (Whisper) and healthcare products (Vicks) in India.
Sells branded goods through distributors and pharmacies. Feminine hygiene is a year-round staple, while Vicks remedies peak in the winter and monsoon months. The brands and know-how come from the US group Procter & Gamble, which controls the company.
Moat: narrow (brand, distribution). Leading, trusted brands (Whisper, Vicks) with deep retail and pharmacy distribution across India.
Headquarters: Mumbai, India · Founded: 1964 · Employees: 712
Size Procter & Gamble Hygiene & Health Care (PGHH.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $2.40B, the 336th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹6,982 on 6 Nov 2026.
Performance Over six months the shares fell 29.4%, against -3.3% for the median peer and 0.0% for the India market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 1.5% over the last twelve months (peer median +3.5%); the operating margin is 24.4% (peer median 10.1%).
Valuation It trades at 27.3× forward earnings against a peer median of 19.2× (5th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 90.7 points above its cost of capital (12.3% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹42.4B | ₹42.9B | ₹45.0B | ₹39.2B | ₹39.0B |
| Revenue growth | — | -5% | +15% | 0% | — |
| Gross profit | ₹23.8B | ₹22.3B | ₹23.2B | ₹17.3B | ₹17.2B |
| EBITDA | ₹10.7B | ₹12.0B | ₹11.9B | ₹8.74B | ₹8.39B |
| Net income | ₹7.91B | ₹8.56B | ₹8.49B | ₹6.78B | ₹5.76B |
| Free cash flow | n/a | ₹9.13B | ₹5.67B | ₹8.11B | ₹5.44B |
| Capital expenditure | n/a | ₹495M | ₹550M | ₹444M | ₹498M |
| Total debt | n/a | ₹8.70M | ₹23.2M | ₹40.3M | ₹51.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Procter & Gamble Hygiene & Health Care PGHH.NS | $2.40B | -29% | -2% | 24% | 27.3× | 15.4% |
| Hindustan Unilever HINDUNILVR.NS | $49.6B | -12% | +6% | 21% | 41.5× | 27.2% |
| Emami EMAMILTD.NS | $1.80B | -15% | +3% | 20% | 21.4× | 21.7% |
| Dabur India DABUR.NS | $7.13B | -19% | +9% | 15% | 32.1× | 27.3% |
| Reckitt Benckiser RKT.L | $47.6B | +22% | -2% | 28% | 16.4× | 1.6% |
| Kenvue KVUE | n/a | +12% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PGHH.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | +3.1% | 9th lowest of 21 |
| 6-month return | -29.4% | -3.3% | 2nd lowest of 21 |
| Distance from 52-week high | -48.3% | -24.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | -1.5% | +3.5% | 4th lowest of 21 |
| Operating margin | 24.4% | 10.1% | 4th highest of 21 |
| Forward P/E | 27.3× | 19.2× | 5th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 15.4% | -0.9% | 5th most demanding of 18 |
| Growth delivered (Del g) | +7.4% | +3.5% | 7th highest of 18 |
| Hurdle (Req g minus delivered) | +8.0 pp | -3.2 pp | 4th most demanding of 18 |
| ROIC minus cost of capital | +90.7 pp | +4.6 pp | highest of 21 |
| EV / EBITDA | 21.1× | 11.1× | 3rd most expensive of 15 |
| Net debt / EBITDA | -0.5× | -0.9× | 7th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.40B | -29% | -2% | 24% | 27.3× | 15.4% | +7.4% |
| LG H&h 051900.KS | South Korea | $2.56B | -8% | -3% | 3% | 18.5× | -0.1% | -4.1% |
| Gillette India GILLETTE.NS | India | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% | +13.0% |
| Softcare 2698.HK | Hong Kong | $2.20B | -5% | +25% | 25% | 14.4× | 8.7% | +20.9% |
| KOSE 4922.T | Japan | $2.16B | +7% | +3% | 4% | 27.2× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.69B | -2% | +4% | 11% | 20.9× | -4.3% | -2.6% |
| Cosmax 192820.KS | South Korea | $2.13B | +21% | +16% | 8% | 16.6× | n/a | n/a |
| Giant Biogene 2367.HK | Hong Kong | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% | +34.9% |
| Pola Orbis 4927.T | Japan | $1.96B | +8% | +1% | 10% | 28.8× | -3.1% | -0.7% |
| Proya Cosmetics 603605.SS | China | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% | +23.1% |
| Kolmar Korea 161890.KS | South Korea | $1.89B | +23% | +13% | 10% | 13.0× | -0.9% | +15.5% |
| Blue Moon 6993.HK | Hong Kong | $1.88B | -15% | -2% | -2% | 93.6× | n/a | n/a |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.84B | -28% | +7% | 9% | 21.2× | 4.5% | +15.3% |
| Lion 4912.T | Japan | $3.19B | +21% | +6% | 8% | 19.9× | -2.4% | +3.5% |
| Emami EMAMILTD.NS | India | $1.80B | -15% | +3% | 20% | 21.4× | 21.7% | +5.6% |
| Hengan Int'l 1044.HK | Hong Kong | $3.28B | -16% | +2% | 11% | 9.1× | -8.8% | -0.1% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.29B | +20% | +4% | 6% | 50.2× | 17.6% | +1.9% |
| Shanghai Jahwa United 600315.SS | China | $1.74B | -13% | +9% | 2% | 18.1× | 17.1% | -2.1% |
| Pigeon 7956.T | Japan | $1.66B | +30% | +7% | 13% | 26.3× | -1.3% | +1.9% |
| Energizer ENR | United States | $1.63B | +26% | +2% | 16% | 7.2× | -5.2% | +1.5% |
| Coty COTY | United States | $3.57B | +64% | -1% | 5% | 13.3× | 11.3% | +4.6% |